Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden

Neoplasia

Volumn 12, Issue 11, 2010, Pages 899-905

  Klover, Peter J ^a   Muller, William J ^b   Robinson, Gertraud W ^a   Pfeiffer, Ruth M ^c   Yamaji, Daisuke ^a   Hennighausen, Lothar ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL;

EID: 78449258706     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10716     Document Type: Article

References (20)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, and Schreiber RD (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3, 991-998.
2. de Weerd NA, Samarajiwa SA, and Hertzog PJ (2007). Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282, 20053-20057.
3. Le Bon A and Tough DF (2002). Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14, 432-436.
4. Durbin JE, Hackenmiller R, Simon MC, and Levy DE (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84, 443-450.
5. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, et al. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAKSTAT signaling pathway. Cell 84, 431-442.
6. Chapgier A, Boisson-Dupuis S, Jouanguy E, Vogt G, Feinberg J, Prochnicka-Chalufour A, Casrouge A, Yang K, Soudais C, Fieschi C, et al. (2006). Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2, e131.
7. Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, Holland SM, Schreiber RD, and Casanova JL (2001). Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293, 300-303.
8. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, and Schreiber RD (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95, 7556-7561.
9. Biswas S and Eisen T (2009). Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat Rev Clin Oncol 6, 478-487.
10. Pavlovsky C, Kantarjian H, and Cortes JE (2009). First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol 84, 287-293.
11. von Stamm U, Brocker EB, von Depka Prondzinski M, Ruiter DJ, Rumke P, Broding C, Carrel S, and Lejeune FJ (1993). Effects of systemic interferon-α (IFN-α) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. Melanoma Res 3, 173-180.
12. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, and Gogas HJ (2008). Next generation of immunotherapy for melanoma. J Clin Oncol 26, 3445-3455.
13. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, et al. (2003). The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J Clin Invest 112, 170-180.
14. Gao C, Mi Z, Guo H, and Kuo PC (2007). Osteopontin regulates ubiquitindependent degradation of Stat1 in murine mammary epithelial tumor cells. Neoplasia 9, 699-706.
15. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, and Weichselbaum RR (2004). STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101, 1714-1719.
16. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, et al. (2008). An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 105, 18490-18495.
17. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, and Sexl V (2006). STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10, 77-87.
18. Ursini-Siegel J, Schade B, Cardiff RD, and Muller WJ (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7, 389-397.
19. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, Pawson T, and Muller WJ (2008). ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 27, 910-920.
20. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, and Hennighausen L (1997). Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25, 4323-4330.